(2S)-butyl 2-((((2R,3R,4R,5R)-5-(2-amino-8-iodo-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)propanoate | 1384068-31-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 吡咯并嘧啶核苷和核苷酸
• 英文名称: (2S)-butyl 2-((((2R,3R,4R,5R)-5-(2-amino-8-iodo-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)propanoate
• 英文别名: butyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2-amino-8-iodo-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate
• CAS: 1384068-31-8
• 化学式: C₂₉H₃₆IN₆O₉P
• 分子量: 770.518
• InChiKey: MYTYWOOKENUMDR-QKNHCRQLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  46
• 可旋转键数：
  14
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  202
• 氢给体数：
  4
• 氢受体数：
  14

文献信息

• SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS
  申请人：McGuigan Chris

  公开号：US20140140955A1

  公开（公告）日：2014-05-22

  This invention is directed to novel compounds of formula (I) having the structure (I) wherein U, V, W, Z, R 1 , X 1 , X 2 , and Y are defined herein. The compounds of formula (I) and pharmaceutical compositions containing these compounds are useful in the treatment of viral infections in mammals mediated, at least in part, by a virus in the Flaviviridae family of viruses, in particular hepatitis C virus (HCV).

  本发明涉及公式（I）的新化合物，其结构为（I），其中U、V、W、Z、R1、X1、X2和Y在此定义。公式（I）的化合物和包含这些化合物的制药组合物在哺乳动物中治疗由Flaviviridae病毒家族中的病毒介导的病毒感染中有用，特别是丙型肝炎病毒（HCV）。
• US9351989B2
  申请人：——

  公开号：US9351989B2

  公开（公告）日：2016-05-31
• [EN] SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS<br/>[FR] NUCLÉOSIDES PURIQUES SUBSTITUÉS, DÉRIVÉS PHOSPHORAMIDATE ET PHOSPHORODIAMIDATE POUR LE TRAITEMENT D'INFECTIONS VIRALES
  申请人：INHIBITEX INC

  公开号：WO2012092484A2

  公开（公告）日：2012-07-05

  This invention is directed to novel compounds of formula (I) having the structure (I) wherein U, V, W, Z, R 1, X1, X2, and Y are defined herein. The compounds of formula (I) and pharmaceutical compositions containing these compounds are useful in the treatment of viral infections in mammals mediated, at least in part, by a virus in the Flaviviridae family of viruses, in particular hepatitis C virus (HCV).